Our recently designed GCGR and GLP-1R co-agonist peptide [17] provided us with a starting point to identify several mutation points on the glucagon (GCG) peptide template to facilitate co-targeting to GIPR and to improve overall resistance to proteolysis
CD36 as a biomarker of atherosclerosis
Factor in the cost of the medication that is not producing results, the ongoing health costs of obesity (medications for blood pressure, diabetes, joint pain), and the opportunity cost of delayed weight loss
[1] [4] The majority of GLP-1-related side effects are most pronounced during dose initiation and escalation, with gradual improvement as your body adapts to the medication
GLP-1 medications such as semaglutide and tirzepatide are prescription-only and require careful patient assessment
This method allowed the goodness of fit to inform upon an appropriate model structure when the actual reaction rates were unknown and, in doing so, provided a useful indication of the possible mechanism by which this process occurs